Recent scientific discoveries concerning therapeutically relevant protein targets that contribute to cancer pathology have opened new possibilities in the search for effective cancer treatments. In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists provide, in an easy-to-understand format, a detailed account of these latest research developments and spell out their implications for cancer drug discovery and clinical application. The authors identify and illuminate selected transcription factor oncoproteins and tumor suppressors, together with nuclear proteins that are central to the phenotype of the tumor cell and including recently elucidated enzymes involved with chromatin control. The emphasis is on new targets and approaches to cancer treatment derived from the cancer cell cycle, gene and chromatin control targets, and angiogenesis. Among the targets considered are E2F, Myc oncoproteins, hypoxic signaling pathways, Mdm2 and ARF, the AP-1 family of transcription factors, histone deacetylase, histone acetyl transferase, apoptin, and nuclear -catenin signaling.
Up-to-date and insightful, Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins shows clearly how our new understanding of critical molecular targets in cancer cells can be applied to cancer drug discovery to provide new drug discovery platforms both for future development and for new target-based medicines for cancer patients.

In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists explain in detail the therapeutically-relevant protein targets that contribute to cancer pathology and spell out their implications for cancer drug discovery and clinical application. The authors identify and illuminate selected transcription factor oncoproteins and tumor suppressors, together with nuclear proteins that are central to the phenotype of the tumor cell involved in chromatin control. The emphasis is on new targets and approaches to cancer treatment derived from the cancer cell cycle, gene control targets, and angiogenesis.